The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.
 
E. Gabriela Chiorean
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Celgene; Eisai; Five Prime Therapeutics; Halozyme; Ipsen; Seagen; Vicus Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Celgene (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene
 
Katherine A Guthrie
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Amgen; ASLAN Pharmaceuticals; Bayer; Biologics; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Lexi Pharma; Merck; Novartis; Rafael Pharmaceuticals; Sanofi
Consulting or Advisory Role - Celgene; Halozyme; Ipsen; Merck; Merrimack; novartis; Rafael Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Other Relationship - Halozyme
 
Elizabeth M. Swisher
Travel, Accommodations, Expenses - Clovis Oncology
 
Florencia Jalikis
No Relationships to Disclose
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Caris Life Sciences; Celgene; Merrimack; Sirtex Medical
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca/MedImmune; Caris Life Sciences; Celgene; Ignyta; Merck; Perthera; Rafael Pharmaceuticals; RenovoRx; Sirtex Medical
Research Funding - ARMO BioSciences (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Curegenix (Inst); FibroGen (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Caris Life Sciences; Perthera; Sirtex Medical
 
Jordan Berlin
Honoraria - Nestle health science
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Bayer Health; BeiGene; Celgene; Cornerstone Pharmaceuticals; Eisai; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; lsk biopharma; Seagen
Research Funding - Bayer (Inst); BeiGene (Inst); boston biomedical (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Pharmacyclics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Bayer; EMD Serono; Nestle health science; Seagen
Other Relationship - AstraZeneca
 
Marcus Smith Noel
Consulting or Advisory Role - Celgene; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Taiho Pharmaceutical
 
Jennifer Marie Suga
No Relationships to Disclose
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Array BioPharma
Research Funding - ARMO BioSciences (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Glenmark (Inst); Halozyme (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Dana Backlund Cardin
Consulting or Advisory Role - Abbvie; Rafael Pharmaceuticals
Research Funding - Advaxis (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Lilly (Inst); Synta (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Danika L. Lew
No Relationships to Disclose
 
Andrew M. Lowy
Honoraria - Celgene
Consulting or Advisory Role - Halozyme; Merck; PFizer
Research Funding - Mitsubishi Tanabe Pharma; Syros Pharmaceuticals
Expert Testimony - Merck
Travel, Accommodations, Expenses - Pfizer
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Exelixis; Genentech